Skip to main content Skip to main navigation menu Skip to site footer

Velocity of response to atypical and typical antipsychotics in the treatment of acute psychosis

  • Siroos Pakseresht ,
  • Hamzeh Rostami ,
  • Maryam Alavi ,


Objective: Antipsychotic drugs are the first-line therapy of psychotic disorders. The aim of this study is to compare the response rapidity of the first and second generation antipsychotics in the treatment of acute psychosis. Methods: In a randomized, double-blind, controlled clinical trial, thirty patients with acute psychosis were randomly allocated into three groups and treated with each of the three antipsychotics: Aripiprazole, risperidone, and perphenazine. The onset of response to each drug was assessed by the Positive and Negative Symptoms Scale. Results: Initial response was seen in 66.6 % of subjects during two weeks of intervention. The mean time of response in the risperidone group was 9.6 days, in the aripiprazole group 11.1 days, and in the perphenazine group 11.3 days. Individuals who received risperidone reached the event sooner than the other two groups. Conclusion: The result of this trial suggested that the response rate of the proposed three drugs was equal, but the onset of action of aripiprazole was slower than risperidone and perphenazine.


  1. Lewis S, Escalona PR, Keith SJ. Phenomenology of Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. New York: Lippinco Williams and Wilkins; 2009. p. 1433-51.
  2. Sadock BJ, Sadock VA, Ruiz P.Serotonin-dopamine Antagonists and Similarly Acting Drugs. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Synopsis of Psychiatry. 11th ed. New York: Lippinco Williams and Wilkins; 2015. p.1023-33.
  3. Tempest M, Sapin C, Beillat M, Robinson P, Treur M. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. J Ment Health Policy Econ. 2015 Dec;18(4):185-200.
  4. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997;23:637-51.
  5. Malla A, Norman R, Schmitz N, Manchanda R, BéchardEvans L, Takhar J, et al. Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychol Med 2006;36:649-58.
  6. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-70.
  7. Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll AL, Suppes T, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000;48:467-76.
  8. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161:473-9.
  9. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry 2000;157:549-59.
  10. Miyamoto S, Lieberman JA, Fleischhacker WW, Aoba A, Marder SR. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, editors. Psychiatry. 2nd edition. Chichester: John Wiley and Sons, Ltd.; 2003. p. 1928-64.
  11. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001;50:912-24.
  12. Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 2003;64 Suppl 12:5-19.
  13. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: Treatment of schizophrenia. J Clin Psychiatry 1999;60:1-80.
  14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
  15. Molins C, Roldán A, Corripio I, Isohanni M, Miettunen J, Seppälä J, Seppälä A, Koponen H, Moilanen J, Jääskeläinen E; m-RESIST Group.. Response to antipsychotic drugs in treatment-resistant schizophrenia: Conclusions based on systematic review. Schizophr Res. 2016 Dec;178(1-3):64-67.
  16. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60.
  17. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs 2009;23:837-55
  18. Zedkova I, Dudova I, Urbanek T, Hrdlicka M. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses. Neuro Endocrinol Le 2011;32:667-70.
  19. Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone. J Affect Disord. 2016 Mar 15;193:381-90.
  20. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res. 2010 Jan;44(1):8-14.
  21. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-45
  22. Siu CO, Agid O, Remington G. Measuring the effects of treatment with antipsychotics. JAMA Psychiatry. 2015 May;72(5):514-5.
  23. Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011 Nov;72(11):1439-44.
  24. Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 2005;38:206-13.
  25. Agid O, Seeman P, Kapur S. The “delayed onset†of antipsychotic action – An idea whose time has come and gone. J Psychiatry Neurosci 2006;31:93-100.
  26. Kane JM, Stroup TS, Marder SR. Schizophrenia: Pharmacological treatment. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. New York: Lippincott Williams and Wilkins; 2009. p. 1547-56.28.
  27. Nordström AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992;106:433-8.
  28. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7:317-21.
  29. Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry. 2011 Oct;199(4):275-80.
  30. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-
  31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
  32. Mousavi SG, Rostami H, Sharbafchi MR, Boroujeni AS, Mahaki B. Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis. Journal of Research in Pharmacy Practice. 2013;2(4):138-144.
  33. van Kammen DP, Hurford I, Marder SR. First-generation antipsychotics. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. New York: Lippincott Williams and Wilkins; 2009. p. 3105-27.
  34. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
  35. World Health Organization. Process of translation and adaptation of instruments. Available from: http://www.who. int/substance_abuse/research_tools/translation/en/. [Last accessed on 2013 Dec 11].
  36. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404.
  37. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085-97.

How to Cite

Pakseresht, S., Rostami, H., & Alavi, M. (2017). Velocity of response to atypical and typical antipsychotics in the treatment of acute psychosis. Bali Medical Journal, 6(3).




Search Panel